Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 91 to 105 of 132 results for thyroid* OR hypothyroid* OR Hyperthyroid* OR goiter

  1. What is the clinical and cost effectiveness of percutaneous thermal ablation for benign thyroid nodules?

    for benign thyroid nodules? Any explanatory notes(if applicable) Source guidance details Comes from guidance Thyroid...

    Research recommendation
    Published
    10 February 2020

  2. Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C (TA75)

    Evidence-based recommendations on interferon alfa (Pegasys or ViraferonPeg) and ribavirin for people with chronic hepatitis C.

    Technology appraisal guidance
    Last updated
    27 November 2013
    View recommendations

    Sections for TA75

  3. Sunitinib for the treatment of gastrointestinal stromal tumours (TA179)

    Evidence-based recommendations on sunitinib (Sutent) for treating gastrointestinal stromal tumours in adults.

    Technology appraisal guidance
    Published
    23 September 2009
    View recommendations

    Sections for TA179

  4. Larotrectinib for treating NTRK fusion-positive solid tumours (TA630)

    Evidence-based recommendations on larotrectinib (Vitrakvi) for treating neurotrophic tyrosine receptor kinase (NTRK) fusion-positive solid tumours in adults and children.

    Technology appraisal guidance
    Published
    27 May 2020
    View recommendations

    Sections for TA630

  5. Thyroid disease

    Awaiting development Reference number: GID-QS10088 Expected publication date: TBC

    Quality standard
    Awaiting development

  6. Satralizumab for treating thyroid eye disease [ID6648]

    Awaiting development Reference number: GID-TA11860 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Veligrotug for treating thyroid eye disease [ID6636]

    Awaiting development Reference number: GID-TA11839 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Palopegteriparatide for treating chronic hypoparathyroidism [ID6380]

    In development Reference number: GID-TA11454 Expected publication date:  23 July 2026

    Technology appraisal guidance
    In development

  9. Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndrome (review of HST31) [ID6598]

    In development Reference number: GID-HST10067 Expected publication date:  19 August 2026

    Highly specialised technologies guidance
    In development

  10. Obicetrapib and obicetrapib–ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia ID6519

    In development Reference number: GID-TA11649 Expected publication date:  14 October 2026

    Technology appraisal guidance
    In development

  11. Dementia: target organ damage (new diagnoses) (IND80)

    This indicator covers the percentage of patients with a new diagnosis of dementia recorded in the preceding 1 April to 31 March with a record of FBC, calcium, glucose, renal and liver function, thyroid function tests, serum vitamin B12 and folate levels recorded between 6 months before or after entering on to the register. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM09

    General practice indicators suitable for use outside of QOF
    Last updated
    31 March 2021

  12. Topical antimicrobial dressings for locally infected leg ulcers: late-stage assessment (HTG751)

    Late stage assessment (LSA) guidance on topical antimicrobial dressings for locally infected leg ulcers.

    HealthTech guidance
    Published
    19 June 2025
    View recommendations

    Sections for HTG751

  13. Cost saving guidance

    reduction in surgical interventions. Capacity savings: £5,100 Guideline on thyroid disease: assessment and management (NG145) Savings...

  14. Translaryngeal tracheostomy (HTG317)

    Evidence-based recommendations on translaryngeal tracheostomy (TLT). This involves passing a tube from inside the windpipe to outside the neck to aid breathing.

    HealthTech guidance
    Published
    23 August 2013
    View recommendations

    Sections for HTG317

  15. Implantation of an opaque intraocular lens for intractable double vision (HTG185)

    Evidence-based recommendations on implantation of an opaque intraocular lens for intractable double vision. This involves replacing the clear lens of one eye with a non-transparent one to block out one of the double images.

    HealthTech guidance
    Published
    25 March 2009
    View recommendations

    Sections for HTG185